Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751646 | 0.86 | GCGR (0.47) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1752482 | 0.86 | GCGR (0.45) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1752085 | 0.86 | GCGR (0.52) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1751838 | 0.83 | GCGR (0.47) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1752600 | 0.82 | GCGR (0.46) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1752361 | 0.82 | GCGR (0.46) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1752584 | 0.81 | GCGR (0.49) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL1751150 | 0.77 | GCGR (0.42) | GCGRLMNADHODHSMN1; SMN2MEN1 | |
| SCHEMBL14282780 | 0.77 | GCGR (0.58) | GCGRLMNADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4756219 | 0.75 | GCGR (0.54) | GCGRLMNADHODHMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614320-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2013-12-24 | — | — | US | disclosed |
| US-20120277432-A1 | Preparation of Aminopyrimidine Compounds | ASTRAZENECA UK LTD. (GB) | 2012-11-01 | — | — | US | disclosed |
| US-8222412-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110160455-A1 | Preparation of Aminopyrimidine Compounds | ASTRAZENECA UK LTD. (GB) | 2011-06-30 | — | — | US | disclosed |
| US-7816528-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2010-10-19 | — | — | US | disclosed |
| US-20080058520-A1 | Preparation of Aminopyrimidine Compounds | MATSUSHITA AKIO | 2008-03-06 | — | — | US | disclosed |
| US-7304156-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2007-12-04 | — | — | US | disclosed |
| EP-1417180-B1 | PREPARATION OF AMINOPYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1417180-A4 | PREPARATION OF AMINOPYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-10-27 | — | — | EP | disclosed |
| US-20040176401-A1 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1417180-A1 | PREPARATION OF AMINOPYRIMIDINE COMPOUNDS | Astrazeneca UK Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003006439-A1 | PREPARATION OF AMINOPYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160455-A1 | Preparation of Aminopyrimidine Compounds | DPYD, UMPS, IDH3B | GCGR 3740/4885LMNA 4126/4885DHODH 192/4885 |
| US-20040176401-A1 | Preparation of aminopyrimidine compounds | DPYD, IDH3B, UMPS | GCGR 3928/4885LMNA 4017/4885DHODH 229/4885 |
| US-20080058520-A1 | Preparation of Aminopyrimidine Compounds | DPYD, UMPS, IDH3B | GCGR 3740/4885LMNA 4126/4885DHODH 192/4885 |
| US-20120277432-A1 | Preparation of Aminopyrimidine Compounds | DPYD, UMPS, IDH3B | GCGR 3740/4885LMNA 4126/4885DHODH 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.